Teva Stock Has More Than Doubled in a Year. Where Will It Be in 3 Years?

Key PointsTeva's pivot from generic drugs to branded drugs has fueled an 100% surge for shares over the past year.

Read the full Veytics brief

We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.